Sentante and the EIC Accelerator: A Remote Robot for Blood Vessels
In an endovascular procedure, a doctor threads catheters and wires through the arteries under continuous X-ray, standing next to the patient. For stroke, where every minute counts, it also means a specialist has to be physically there. Sentante, the product of the Lithuanian company UAB Inovatyvi Medicina, founded in Kaunas in 2017, is a robot that moves standard catheters and guidewires at the bedside while the doctor controls it from a remote workstation, with haptic feedback.
CORDIS records an EU contribution of €2,491,365.63 towards a €3,559,093.75 project; this is the project allocation, not proof of the amount paid. The EIC Fund later joined a €6 million seed round led by Practica Capital. During the project, Sentante advanced from preclinical testing to readiness for clinical testing; its first-in-human peripheral study began shortly before the project closed and completed in October 2024. The company announced a CE mark for its robotic platform in May 2026. Its separate remote-stroke programme remains preclinical and on an FDA development pathway.
Company file
- Legal entity
- UAB Inovatyvi Medicina, Lithuania
- Brand
- Sentante
- Founded
- 2017, Kaunas
- Co-founders
- Edvardas Satkauskas (CEO), Tomas Baltrūnas (CMO)
- Regulatory
- Company-announced CE mark (May 2026); FDA Breakthrough Device designation for the remote-stroke system (2025), which is not FDA clearance
- Investors
- Practica Capital (lead), EIC Fund
- EIC project
- SER, 1 May 2022 to 31 Jul 2024, closed
- EIC funding
- Grant first; EIC Fund in the 2023 seed round
Where Sentante Stands Today
On 21 May 2026 MedTech Dive reported the company’s CE-mark announcement and said it cleared the robotic platform for sale in Europe; the company described initial rollout and clinician training. Co-founder Tomas Baltrūnas said it was "transitioning to a commercial stage organization". The CE-marked platform’s initial commercial deployment is in vascular surgery and interventional radiology, according to the company’s August 2026 announcement. Remote stroke treatment is on a separate US development path: the FDA Breakthrough Device designation and its Total Product Life Cycle Advisory Program are not marketing clearance or clinical-trial authorization.
The EIC Scaling Club, which profiles the company, lists an FDA Breakthrough Device designation received in September 2025. In November 2025 a neurosurgeon in Florida used the system to perform a transatlantic thrombectomy on a cadaver in Scotland. On 20 August 2026 Sentante announced commercial deployment in vascular surgery and interventional radiology. It reported 100% technical success and no device-related complications in the ESSENTIAL peripheral first-in-human study, which involved 10 patients and 21 procedures. These are small-study results reported by the company; the announcement did not name commercial hospitals or disclose sales.
The Technology: The Doctor Leaves the Room
The robot's bedside unit grips and advances ordinary, off-the-shelf catheters and guidewires, so hospitals do not need special instruments. The doctor works from a console, feeling resistance through haptic feedback, away from the X-ray source. A study in pigs published in Cardiovascular and Interventional Radiology in February 2026 completed all 18 procedures, including stenting, embolisation and angioplasty, without switching to manual control, with minor vessel trauma in three of 16 target vessels. Three of its authors work for or hold shares in the company.
The evidence
18 of 18 procedures completed robotically in animals
Porcine study of six animals: stenting, embolisation and angioplasty done without converting to manual. Three of the authors are employed by or hold shares in the company.
Cardiovascular and Interventional Radiology, February 2026.
"The first tele-operated endovascular robot in the world which is capable of performing an entire endovascular procedure."
Inovatyvi Medicina’s beneficiary-submitted SER report, hosted by CORDISWhat the EIC Project Promised, and What CORDIS Shows
The EIC project
EU contribution: 70% of recorded project cost
SER ran from May 2022 to July 2024. The recorded EU contribution is not a payment reconciliation; the EIC Fund separately joined the 2023 seed round.
CORDIS project 190123213. Values in € millions; remaining project cost is not labelled as company cash.
SER ran from May 2022 to July 2024. The beneficiary-submitted CORDIS report says the project moved the system from a prototype at technology readiness level 6 to clinical-trial readiness at level 7 through cadaver, animal and GLP animal tests, and reports that a first-in-human study was underway and new patent applications had been filed. The ESSENTIAL trial registry records it started on 19 July 2024, before the project’s 31 July close, and completed on 30 October 2024. The peer-reviewed JACC: Cardiovascular Interventions study describes 10 patients and 21 peripheral procedures. CORDIS anticipated CE marking after the project; the company announced its CE mark in May 2026.
- Preclinical validationDeliveredCadaver, animal and GLP studies; 18/18 procedures in pigs.
- First-in-human trialStarted during project; completed afterRegistry dates: 19 July–30 October 2024; 10 patients and 21 peripheral procedures.
- CE markingDeliveredMay 2026, after the project.
- US market and remote strokeIn progressBreakthrough designation; no FDA clearance or stroke trial yet.
What Has Happened Since the Award
The record
From a Kaunas prototype to a CE-marked robot
The peripheral first-in-human study began shortly before project close and completed in October 2024; the company announced CE marking in May 2026.
- 2017Company foundedKaunas, Lithuania; Edvardas Satkauskas (CEO) and Tomas Baltrūnas (CMO)
- Jun 2021EIC Accelerator cut-offSER: a tele-operated robot for fully robotic endovascular procedures
- May 2022EIC project startsCadaver, animal and GLP studies; first-in-human study begins shortly before project close€2.49M EU contribution
- Dec 2023Seed roundLed by Practica Capital, with the EIC Fund€6M
- Jul 2024EIC project closesFirst-in-human study underway; TRL 7
- 2025FDA Breakthrough DeviceDesignation, plus a transatlantic remote stroke demonstration
- Feb 2026FDA TAP programmeAccepted into the FDA's advisory programme for the path to a stroke trial
- May 2026Company announces CE markPlatform enters initial commercial rollout for vascular surgery and interventional radiology
EIC Scaling Club, CORDIS, Cardiovascular and Interventional Radiology and MedTech Dive.
The Money
The money
A grant, then a seed round with the EIC Fund
Disclosed funding in millions of euros. The EIC Fund's share of the seed round was not disclosed.
CORDIS; EIC Scaling Club.
Sentante announced a €6 million seed round led by Practica Capital with EIC Fund participation in December 2023; the EIC’s share was not disclosed. As of 2 November 2026, we found no later funding announcement in the company’s news, EIC/Practica portfolio information and the public coverage reviewed. The search does not establish that no later financing occurred. The company has since announced commercial rollout and continues to develop the US stroke programme.
What cannot be checked
How many patients have been treated with the robot, which hospitals use it commercially, and the company's revenue and cash position are not public.
Why Europe Should Care
Remote endovascular robotics could one day let a stroke specialist treat patients in hospitals that do not have one and reduce clinicians’ radiation exposure. Sentante is a Lithuanian company with a company-announced CE-marked platform entering initial commercial use in vascular surgery and interventional radiology. Remote stroke treatment remains on a separate preclinical and FDA development path. The EIC project contribution and later EIC Fund seed participation are separate forms of support.
What the project promised
A tele-operated endovascular robot advanced to clinical-trial readiness, with CE marking planned after the project.
What the record shows
A 10-patient peripheral first-in-human study, published animal data and a company-announced CE mark; remote stroke treatment remains preclinical.
The Verdict
Delivered, and now it has to sell
The CORDIS report says the project reached clinical-trial readiness and began its first-in-human peripheral study. The 10-patient study completed after the project closed, and the company announced a CE mark in May 2026. The EIC Fund later joined a seed round. Commercial deployment is now announced for vascular surgery and interventional radiology; remote stroke treatment remains preclinical. Larger clinical studies and commercial uptake will determine what follows.
Sentante has not been asked for comment for this article. It is based entirely on public records, company statements, scientific publications and EU project data, linked throughout.
Sources
- CORDIS, SER fact sheet and periodic report
- MedTech Dive, CE mark, 21 May 2026
- EIC Scaling Club, Sentante profile
- Unite.AI, commercial deployment, August 2026 and Medical Design & Outsourcing, transatlantic demonstration
- Cardiovascular and Interventional Radiology, February 2026 and JACC: Cardiovascular Interventions, first in human
- ClinicalTrials.gov, ESSENTIAL first-in-human study and Sentante, commercial rollout announcement
- Sentante, CE-mark announcement and €6 million seed round announcement
- European Commission, 2021 EIC selection list (grant first)
Industry
HealthMedical devices
- Focus
- Cardiovascular devices
- Technologies
- Robotics
- Haptics
- Keywords
- Stroke
- Endovascular procedures
- Remote surgery
- Surgical robotics